Stryker Corporation (SYK) — Q3 2021 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2021. Dollar amounts are in millions except per-share data. Stryker makes medical technology products across Orthopaedics, MedSurg, and Neurotechnology and Spine.
Financial performance
| Metric | Q3 2021 | Q3 2020 | Nine months 2021 | Nine months 2020 |
|---|---|---|---|---|
| Net sales | $4,160 | $3,737 | $12,407 | $10,089 |
| Gross profit / margin | $2,642 / 63.5% | $2,461 / 65.9% | $7,923 / 63.9% | $6,340 / 62.8% |
| Operating income / margin | $574 / 13.8% | $859 / 23.0% | $1,765 / 14.2% | $1,474 / 14.6% |
| Net earnings | $438 | $621 | $1,332 | $1,031 |
| Diluted EPS | $1.14 | $1.63 | $3.48 | $2.71 |
| Adjusted diluted EPS (non-GAAP) | $2.20 | $2.14 | $6.38 | $4.62 |
Q3 sales grew 11.3% reported (10.7% constant currency); nine-month sales grew 23.0% (21.0% constant currency). Management attributed growth mainly to higher unit volumes, with acquisitions materially contributing, particularly to Orthopaedics. Q3 adjusted operating margin was 25.4%, down from 28.0%; nine-month adjusted margin was 25.0%, up from 22.3%. Adjusted measures are non-GAAP and exclude items such as acquisition costs, amortization, restructuring, regulatory costs and recalls.
Segments and notable changes
- Q3 sales: Orthopaedics $1,529 (up 16.1%), MedSurg $1,755 (up 9.4%), and Neurotechnology and Spine $876 (up 7.3%). Orthopaedics growth included the Wright acquisition; excluding acquisitions and divestitures, constant-currency Orthopaedics sales declined 1.2% in the quarter.
- Q3 GAAP operating income and earnings fell despite higher sales. The filing cites higher acquisition and integration costs, restructuring and other charges, amortization, and a $105 China-related asset impairment. Adjusted Q3 diluted EPS rose 2.8% to $2.20.
- Nine-month net earnings rose 29.2%; adjusted diluted EPS increased 38.1%. Higher volume and acquisition contributions supported sales, while costs and acquisition-related items affected reported profitability.
- Research and development expense rose 26.4% in Q3, which management linked to investment in product development, technology and integration.
Cash, debt and liquidity
- Nine-month operating cash flow was $2,263, compared with $2,040 a year earlier. Investing cash outflow was $545, including $226 of acquisitions net of cash acquired and $319 of capital expenditures.
- Financing cash outflow was $2,077, principally reflecting repayment of $750 of notes and a $400 term loan, plus $713 of dividends. Cash declined $380 during the nine months to $2,563.
- At September 30, cash and marketable securities totaled $2,639; current assets exceeded current liabilities by $5,011. Total debt was $12,651, versus $13,991 at December 31, 2020. No borrowings were outstanding under the prior revolving credit facility or commercial paper program at quarter-end.
- After quarter-end, Stryker entered a $2.25 billion revolving credit agreement maturing October 2026, with a maximum leverage covenant of 3.75:1, subject to specified acquisition-related provisions. The company reported compliance with its covenants at September 30.
Outlook, risks and contingencies
- The filing provides no specific full-year revenue or earnings guidance. Management said COVID-19 and the Delta variant, rising hospitalizations and staffing shortages slowed elective-procedure recovery in Q3, particularly affecting Orthopaedics and Spine. Supplier, vendor, distributor and manufacturing operations may also be disrupted.
- China volume-based procurement programs are expected to put pressure on prices for joint replacement and trauma products. Stryker recorded a $105 impairment in Q3; China represented about 2% of 2020 revenue. The future scope of procurement programs for Spine was uncertain.
- Product-recall matters remain a significant exposure. For the first nine months, Stryker recorded $98 in recall charges and paid $180, primarily related to Rejuvenate and ABG II hip stems. Estimated remaining probable losses were approximately $410 to $545; reserves represented the minimum of that range. Actual outcomes could be materially different.
- Other legal and product-liability claims may result in additional costs or adverse outcomes. Management cautioned that actual results may differ materially from forward-looking statements, including due to pandemic effects and other risks described in the 2020 Form 10-K.
- Share repurchases were suspended through 2021; none were made in the first nine months. Remaining authorization was $1,033 at September 30.
Key facts for investors to verify
- How elective procedure volumes, hospital staffing constraints and supply conditions affect subsequent sales and margins.
- Whether China procurement pricing and program expansion cause further revenue pressure or impairments.
- Progress, payments, reserves and potential variability in the estimated $410–$545 remaining recall loss range.
- How much reported growth and adjusted earnings depend on acquisitions and excluded non-GAAP items; the filing’s Q3 discussion gives differing ex-acquisition constant-currency growth figures (4.5% in the overview and 5.2% in the detailed analysis).
- Debt, liquidity and compliance under the new revolving credit agreement, and the pace of future debt repayment and capital returns.